125 related articles for article (PubMed ID: 21388856)
1. Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression.
Dejonckheere E; Vandenbroucke RE; Libert C
Cytokine Growth Factor Rev; 2011 Apr; 22(2):73-81. PubMed ID: 21388856
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-8: cleavage can be decisive.
Van Lint P; Libert C
Cytokine Growth Factor Rev; 2006 Aug; 17(4):217-23. PubMed ID: 16820317
[TBL] [Abstract][Full Text] [Related]
3. [Extracellular matrix metalloproteinases--perspectives of their use in medicine].
Kotulska-Wolwender K; Larysz-Brysz M; Fus Z; Korczyńska I; Górka D; Lewin-Kowalik J
Wiad Lek; 2002; 55(7-8):463-71. PubMed ID: 12428575
[TBL] [Abstract][Full Text] [Related]
4. Periodontology in the age of inflammation: a changing landscape.
Cochran D
J Am Coll Dent; 2009; 76(1):23-6. PubMed ID: 19537479
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory disease processes and interactions with nutrition.
Calder PC; Albers R; Antoine JM; Blum S; Bourdet-Sicard R; Ferns GA; Folkerts G; Friedmann PS; Frost GS; Guarner F; Løvik M; Macfarlane S; Meyer PD; M'Rabet L; Serafini M; van Eden W; van Loo J; Vas Dias W; Vidry S; Winklhofer-Roob BM; Zhao J
Br J Nutr; 2009 May; 101 Suppl 1():S1-45. PubMed ID: 19586558
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases involvement in pathologic conditions.
Amălinei C; Căruntu ID; Giuşcă SE; Bălan RA
Rom J Morphol Embryol; 2010; 51(2):215-28. PubMed ID: 20495735
[TBL] [Abstract][Full Text] [Related]
7. Versican in health and disease.
Theocharis AD
Connect Tissue Res; 2008; 49(3):230-4. PubMed ID: 18661349
[TBL] [Abstract][Full Text] [Related]
8. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice.
Balbín M; Fueyo A; Tester AM; Pendás AM; Pitiot AS; Astudillo A; Overall CM; Shapiro SD; López-Otín C
Nat Genet; 2003 Nov; 35(3):252-7. PubMed ID: 14517555
[TBL] [Abstract][Full Text] [Related]
9. Oxidative damage to extracellular matrix and its role in human pathologies.
Rees MD; Kennett EC; Whitelock JM; Davies MJ
Free Radic Biol Med; 2008 Jun; 44(12):1973-2001. PubMed ID: 18423414
[TBL] [Abstract][Full Text] [Related]
10. Post-translational modifications of the extracellular matrix are key events in cancer progression: opportunities for biochemical marker development.
Leeming DJ; Bay-Jensen AC; Vassiliadis E; Larsen MR; Henriksen K; Karsdal MA
Biomarkers; 2011 May; 16(3):193-205. PubMed ID: 21506694
[TBL] [Abstract][Full Text] [Related]
11. [Role of matrix metalloproteinase-3 in joint destruction in rheumatoid arthritis].
Sugiyama E
Clin Calcium; 2007 Apr; 17(4):528-34. PubMed ID: 17404481
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver.
Elli L; Bergamini CM; Bardella MT; Schuppan D
Dig Liver Dis; 2009 Aug; 41(8):541-50. PubMed ID: 19195940
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular disease in rheumatoid arthritis: a step forward.
Myasoedova E; Gabriel SE
Curr Opin Rheumatol; 2010 May; 22(3):342-7. PubMed ID: 20164773
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
Avouac J; Allanore Y
Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
[TBL] [Abstract][Full Text] [Related]
16. [Fibrinolytic activity of the blood and synovial fluid in patients with rheumatoid arthritis with systemic manifestations].
Erov NK
Ter Arkh; 1988; 60(4):94-100. PubMed ID: 3394106
[TBL] [Abstract][Full Text] [Related]
17. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
Fraser A; Fearon U; Billinghurst RC; Ionescu M; Reece R; Barwick T; Emery P; Poole AR; Veale DJ
Arthritis Rheum; 2003 Nov; 48(11):3085-95. PubMed ID: 14613270
[TBL] [Abstract][Full Text] [Related]
18. Assessment of endothelial function as a marker of cardiovascular risk in patients with rheumatoid arthritis.
Khan F
Int J Rheum Dis; 2010 Aug; 13(3):189-95. PubMed ID: 20704614
[TBL] [Abstract][Full Text] [Related]
19. Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases.
Szczepanska-Sadowska E; Cudnoch-Jedrzejewska A; Ufnal M; Zera T
J Physiol Pharmacol; 2010 Oct; 61(5):509-21. PubMed ID: 21081794
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein, cardiovascular disease, and periodontal disease.
Goldie MP
Int J Dent Hyg; 2004 Aug; 2(3):139-41. PubMed ID: 16451479
[No Abstract] [Full Text] [Related]
[Next] [New Search]
